Economic Evaluation of First-Line Treatments for Metastatic Renal Cell Carcinoma: A Cost-Effectiveness Analysis in A Health Resource–Limited Setting

PLoS ONE ◽

10.1371/journal.pone.0032530 ◽

2012 ◽

Vol 7 (3) ◽

pp. e32530 ◽

Author(s):

Bin Wu ◽

Baijun Dong ◽

Yuejuan Xu ◽

Qiang Zhang ◽

Jinfang Shen ◽

...

Keyword(s):

Renal Cell Carcinoma ◽

Economic Evaluation ◽

Cost Effectiveness ◽

Cell Carcinoma ◽

Health Resource ◽

Effectiveness Analysis ◽

Resource Limited ◽

Limited Setting

Download Full-text

A Cost-Effectiveness Analysis: First-Line Avelumab Plus Axitinib Versus Sunitinib for Advanced Renal-Cell Carcinoma

Frontiers in Pharmacology ◽

10.3389/fphar.2020.00619 ◽

2020 ◽

Vol 11 ◽

Author(s):

Peiyao Lu ◽

Weiting Liang ◽

Jiahao Li ◽

Yanming Hong ◽

Zhuojia Chen ◽

...

Keyword(s):

Renal Cell Carcinoma ◽

Cost Effectiveness ◽

Cell Carcinoma ◽

Cost Effectiveness Analysis ◽

Advanced Renal Cell Carcinoma ◽

Effectiveness Analysis

Download Full-text

A Cost‐Effectiveness Analysis of Nivolumab and Ipilimumab Versus Sunitinib in First‐Line Intermediate‐ to Poor‐Risk Advanced Renal Cell Carcinoma

The Oncologist ◽

10.1634/theoncologist.2018-0656 ◽

2019 ◽

Vol 24 (3) ◽

pp. 366-371 ◽

Author(s):

Daniel Reinhorn ◽

Michal Sarfaty ◽

Moshe Leshno ◽

Assaf Moore ◽

Victoria Neiman ◽

...

Keyword(s):

Renal Cell Carcinoma ◽

Cost Effectiveness ◽

Cell Carcinoma ◽

Cost Effectiveness Analysis ◽

Advanced Renal Cell Carcinoma ◽

Poor Risk ◽

Effectiveness Analysis

Download Full-text

Cost-effectiveness Analysis of Pembrolizumab Plus Axitinib Versus Sunitinib in First-line Advanced Renal Cell Carcinoma in China

Clinical Drug Investigation ◽

10.1007/s40261-019-00820-6 ◽

2019 ◽

Vol 39 (10) ◽

pp. 931-938 ◽

Author(s):

Jun Chen ◽

Gaoyun Hu ◽

Zhuo Chen ◽

Xiaomin Wan ◽

Chongqing Tan ◽

...

Keyword(s):

Renal Cell Carcinoma ◽

Cost Effectiveness ◽

Cell Carcinoma ◽

Cost Effectiveness Analysis ◽

Advanced Renal Cell Carcinoma ◽

Effectiveness Analysis

Download Full-text

Economic implications of the first-line treatment of advanced renal cell carcinoma in Thailand: A cost-effectiveness analysis.

Journal of Clinical Oncology ◽

10.1200/jco.2010.28.15_suppl.e15136 ◽

2010 ◽

Vol 28 (15_suppl) ◽

pp. e15136-e15136

Author(s):

N. Topibulpong ◽

S. Tanasanvimon ◽

N. Parinyanitikul ◽

C. Vinayanuwattikun ◽

V. Sriuranpong

Keyword(s):

Renal Cell Carcinoma ◽

Cost Effectiveness ◽

Cell Carcinoma ◽

Cost Effectiveness Analysis ◽

Line Treatment ◽

Economic Implications ◽

Effectiveness Analysis ◽

First Line Treatment

Download Full-text

An updated cost-effectiveness analysis of pazopanib versus sunitinib as first-line treatment for locally advanced or metastatic renal cell carcinoma in Italy

Journal of Medical Economics ◽

10.1080/13696998.2020.1839240 ◽

2020 ◽

pp. 1-9

Author(s):

Stefano Capri ◽

Camillo Porta ◽

Claudia Condorelli ◽

Eleonora Premoli ◽

Ankur Khare ◽

...

Keyword(s):

Renal Cell Carcinoma ◽

Cost Effectiveness ◽

Cell Carcinoma ◽

Metastatic Renal Cell Carcinoma ◽

Locally Advanced ◽

Line Treatment ◽

Effectiveness Analysis ◽

First Line Treatment

Download Full-text

Cost-Effectiveness Analysis of Using Everolimus or Axitinib in Patients with Metastatic Renal Cell Carcinoma WHO Have Failed to Use of Pazopanib or Sunitinib in First-Line Treatment

Value in Health ◽

10.1016/j.jval.2016.09.2223 ◽

2016 ◽

Vol 19 (7) ◽

pp. A735 ◽

Author(s):

ME Romero Prada ◽

LM Huerfano ◽

NC Roa Cardenas

Keyword(s):

Renal Cell Carcinoma ◽

Cost Effectiveness ◽

Cell Carcinoma ◽

Metastatic Renal Cell Carcinoma ◽

Cost Effectiveness Analysis ◽

Line Treatment ◽

Effectiveness Analysis ◽

First Line Treatment

Download Full-text

PCN70 COST EFFECTIVENESS ANALYSIS OF SUNITINIB, BEVACIZUMAB + INTERFERON-ALFA AND TEMSIROLIMUS AS FIRST-LINE THERAPY OF METASTATIC RENAL CELL CARCINOMA IN SWEDEN

Value in Health ◽

10.1016/s1098-3015(10)74321-7 ◽

2009 ◽

Vol 12 (7) ◽

pp. A270 ◽

Author(s):

E Remák ◽

H Vioix ◽

R Sandin ◽

U Harmenberg ◽

A Ullén ◽

...

Keyword(s):

Renal Cell Carcinoma ◽

Cost Effectiveness ◽

Cell Carcinoma ◽

Metastatic Renal Cell Carcinoma ◽

Interferon Alfa ◽

First Line Therapy ◽

Effectiveness Analysis ◽

Download Full-text

A Cost-Effectiveness Analysis of Nivolumab Plus Ipilimumab Versus Pembrolizumab Plus Axitinib and Versus Avelumab Plus Axitinib in First-Line Treatment of Advanced Renal Cell Carcinoma

Clinical Genitourinary Cancer ◽

10.1016/j.clgc.2021.01.009 ◽

2021 ◽

Author(s):

Rebecca Shay ◽

Andrew Nicklawsky ◽

Dexiang Gao ◽

Elaine T. Lam

Keyword(s):

Renal Cell Carcinoma ◽

Cost Effectiveness ◽

Cell Carcinoma ◽

Cost Effectiveness Analysis ◽

Advanced Renal Cell Carcinoma ◽

Line Treatment ◽

Effectiveness Analysis ◽

First Line Treatment

Download Full-text

PCN127 COST-EFFECTIVENESS ANALYSIS OF NIVOLUMAB IN COMBINATION WITH IPILIMUMAB COMPARED WITH CURRENTLY AVAILABLE FIRST-LINE TREATMENTS IN PATIENTS WITH PREVIOUSLY UNTREATED METASTATIC RENAL CELL CARCINOMA IN THE UNITED STATES

Value in Health ◽

10.1016/j.jval.2019.04.251 ◽

2019 ◽

Vol 22 ◽

pp. S80

Author(s):

N. Tanova ◽

S. Yang ◽

L.H. Cheung ◽

V. Genestier ◽

K.M. Gooden ◽

...

Keyword(s):

United States ◽

Renal Cell Carcinoma ◽

Cost Effectiveness ◽

Cell Carcinoma ◽

Metastatic Renal Cell Carcinoma ◽

The United States ◽

Cost Effectiveness Analysis ◽

Effectiveness Analysis

Download Full-text

A cost-effectiveness analysis of Nivolumab and Ipilimumab versus Sunitinib in first line intermediate-poor risk advanced Renal Cell Carcinoma

European Urology Supplements ◽

10.1016/s1569-9056(18)33792-8 ◽

2018 ◽

Vol 17 (14) ◽

pp. e2941

Author(s):

D. Reinhorn ◽

M. Sarfaty ◽

M. Leshno ◽

V. Neiman ◽

E. Rosenbaum ◽

...

Keyword(s):

Renal Cell Carcinoma ◽

Cost Effectiveness ◽

Cell Carcinoma ◽

Cost Effectiveness Analysis ◽

Advanced Renal Cell Carcinoma ◽

Poor Risk ◽

Effectiveness Analysis

Download Full-text